Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence and Awareness of Acute Bacterial Skin and Skin Structure Infection
4.2.2 Increasing Pipeline Development Activities
4.2.3 Rising Healthcare Spending Across the World
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies by Government Bodies, and Patent Expiration
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type of Infection
5.1.1 Hospital Acquired ABSSI
5.1.2 Community acquired ABSSI
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Topical
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Paratek Pharmaceuticals, Inc.,
6.1.2 Melinta Therapeutics, Inc.,
6.1.3 Allergan plc,
6.1.4 Merck & Co., Inc.,
6.1.5 AccordHealthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.),
6.1.6 Sandoz Inc. (a subsidiary of Novartis),
6.1.7 Glenmark Pharmaceuticals Ltd
6.1.8 Cadila Healthcare Ltd.,
6.1.9 Teva Pharmaceutical Industries Ltd.
6.1.10 Pfizer Inc.
6.1.11 Cumberland pharmaceutical inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS